✦ LIBER ✦

P.2.c.006 Efficacy and clinical relevance of vilazodone in the treatment of major depressive disorder: a pooled analysis of phase III clinical trials

✍ Scribed by A. Khan; W. Song; J. Edwards; A. Ruth

Book ID: 118599177
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 75 KB
Volume: 22
Category: Article
ISSN: 0924-977X
DOI: 10.1016/s0924-977x(12)70379-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P.2.c.020 The efficacy and safety of lev

P.2.c.020 The efficacy and safety of levomilnacipran in the treatment of major depressive disorder: results from a phase III clinical trial

✍ A. Bose; C. Chen; C. Gommoll; A. Ruth; J. Terner-Rosenthal 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 71 KB

P.2.a.009 Pooled analysis: 2 randomised

P.2.a.009 Pooled analysis: 2 randomised clinical trials confirms superiority of escitalopram over paroxetine in treatment of major depressive disorder

✍ S. Kasper; D. Baldwin; J.P. Boulenger 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 69 KB

P.2.c.006 Analysis of longitudinal clini

P.2.c.006 Analysis of longitudinal clinical scores in major depressive disorder trials: comparison of linear and non-linear mixed effect modelling

✍ L. Iavarone; R. Gomeni 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 195 KB

Safety and tolerability of duloxetine in

Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials

✍ James I. Hudson; Madelaine M. Wohlreich; Daniel K. Kajdasz; Craig H. Mallinckrod 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 185 KB 👁 2 views

## Abstract ## Objective To examine the safety and tolerability of the antidepressant duloxetine across multiple studies for major depressive disorder (MDD). ## Method Safety data were integrated from the acute phases of eight double‐blind, placebo‐controlled trials in which patients were random

PMH52 Levomilnacipran in the Treatment o

PMH52 Levomilnacipran in the Treatment of Major Depressive Disorder: Functional Health and Well-Being Efficacy Results from a Phase III Clinical Trial

✍ S.I. Blum; S. Tourkodimitris; A. Ruth 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB

P.2.c.022 Levomilnacipran in the treatme

P.2.c.022 Levomilnacipran in the treatment of major depressive disorder: functional health and well-being efficacy results from a phase III trial

✍ S. Blum; S. Tourkodimitris; A. Ruth; J. Terner-Rosenthal 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 74 KB